CIAS
LKFT

Capital Investment Advisory Services’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Capital Investment Advisory Services’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-48
Closed -$9K – 1402
2019
Q2 		$9K Buy
+48
New +$5.7K ﹤0.01% 992

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Capital Investment Advisory Services's LKFT Position: Q3 2019 in Review

Capital Investment Advisory Services sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2019, closing a stake of 48 shares — an estimated $9K sold.

Capital Investment Advisory Services first reported a position in LKFT in Q2 2019 and held it in 1 quarter. The position peaked at $9K in Q2 2019. 111 funds tracked by Wall St. Rank hold LKFT as of Q3 2019.

  • Capital Investment Advisory Services reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 48 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2019, an estimated $9K.
  • Capital Investment Advisory Services first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2019 and held it in 1 quarter.
  • Capital Investment Advisory Services's Lakefront Biotherapeutics American Depositary Shares position peaked at $9K in Q2 2019.
  • 111 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2019.

Based on Capital Investment Advisory Services's 13F filing for Q3 2019, filed 17 Oct 2019.